Trial
NCT03170232
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Pulmonary Disease, Chronic Obstructive
Intervention
Danirixin 35 mg tablets
Why stopped
Terminated based on lack of efficacy seen in participants taking danirixin in dose ranging study and Sponsor decision to stop development of danirixin for COPD
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-31